Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. CEO Rand Sutherland will engage in a fireside chat on December 3, 2024, at 2:00 p.m. ET. The presentation will be accessible via live webcast in the 'Events' section of the company's website, with a replay available for 90 days afterward.
Upstream Bio (Nasdaq: UPB), un'azienda in fase clinica focalizzata nello sviluppo di trattamenti per le malattie infiammatorie e i disturbi respiratori gravi, ha annunciato la sua partecipazione alla 36a Conferenza Sanitaria Annuale di Piper Sandler. Il CEO Rand Sutherland parteciperà a una chiacchierata informale il 3 dicembre 2024, alle 14:00 ET. La presentazione sarà accessibile tramite webcast live nella sezione 'Eventi' del sito web dell'azienda, con una registrazione disponibile per 90 giorni dopo.
Upstream Bio (Nasdaq: UPB), una empresa en etapa clínica centrada en el desarrollo de tratamientos para enfermedades inflamatorias y trastornos respiratorios severos, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El CEO Rand Sutherland participará en una charla informal el 3 de diciembre de 2024 a las 2:00 p.m. ET. La presentación estará disponible a través de una transmisión en vivo en la sección 'Eventos' del sitio web de la empresa, con una repetición disponible durante 90 días después.
Upstream Bio (Nasdaq: UPB), 염증성 질환 및 중증 호흡기 질환 치료 개발에 중점을 둔 임상 단계 회사가 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO Rand Sutherland는 2024년 12월 3일 오후 2시 (ET)에 편안한 대화에 참여할 예정입니다. 프레젠테이션은 회사 웹사이트의 '이벤트' 섹션에서 실시간 웹캐스트를 통해 접근할 수 있으며, 이후 90일 동안 다시 시청할 수 있습니다.
Upstream Bio (Nasdaq: UPB), une entreprise en phase clinique spécialisée dans le développement de traitements pour les maladies inflammatoires et les troubles respiratoires graves, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. Le PDG Rand Sutherland participera à une discussion informelle le 3 décembre 2024 à 14h00 ET. La présentation sera accessible via un webinaire en direct dans la section 'Événements' du site Web de l'entreprise, avec une rediffusion disponible pendant 90 jours après.
Upstream Bio (Nasdaq: UPB), ein unternehmenseigener Anbieter, der sich auf die Entwicklung von Behandlungen für entzündliche Erkrankungen und schwere Atemwegserkrankungen konzentriert, hat seine Teilnahme an der 36. Jahrestagung im Gesundheitswesen von Piper Sandler bekannt gegeben. CEO Rand Sutherland wird am 3. Dezember 2024 um 14:00 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Live-Webcast im Bereich 'Veranstaltungen' auf der Website des Unternehmens zugänglich sein, mit einer Wiederholung, die 90 Tage lang verfügbar ist.
- None.
- None.
WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio’s CEO, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 2:00 p.m. ET.
A live webcast of the presentation will be available under the “Events” tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
FAQ
When is Upstream Bio (UPB) presenting at the Piper Sandler Healthcare Conference 2024?
How long will Upstream Bio's (UPB) Piper Sandler Conference presentation be available for replay?
What type of diseases does Upstream Bio (UPB) focus on treating?
Where can I watch Upstream Bio's (UPB) Piper Sandler Conference presentation?
